Edition:
United Kingdom

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

531.20INR
6:54am GMT
Change (% chg)

Rs-0.95 (-0.18%)
Prev Close
Rs532.15
Open
Rs533.65
Day's High
Rs536.85
Day's Low
Rs530.00
Volume
337,943
Avg. Vol
959,055
52-wk High
Rs972.95
52-wk Low
Rs530.00

Select another date:

BRIEF-Glenmark Pharmaceuticals Meets Primary Clinical Endpoint In Phase 3 Study Of Ryaltris

* SAYS MET ITS PRIMARY CLINICAL ENDPOINT IN A PHASE 3 STUDY EVALUATING SAFETY OF RYALTRIS

BRIEF-Glenmark Pharma Says Closed DCP For Generic Seretide Accuhaler In Nordic Region​

* ANNOUNCES CLOSURE OF DECENTRALISED REGISTRATION PROCEDURE (DCP) FOR GENERIC SERETIDE ACCUHALER IN NORDIC REGION​ Source text - http://bit.ly/2ByD8zw Further company coverage:

BRIEF-Glenmark Pharma Says U.S. FDA issues 7 Form 483 observations for co's ‍Baddi Unit

* GLENMARK PHARMACEUTICALS SAYS ‍BADDI UNIT UNDERWENT AN U.S. FDA AUDIT FROM NOVEMBER 6, 2017 TO NOVEMBER 11, 2017

BRIEF-Glenmark Pharmaceuticals gets ANDA approval for HAILEY Fe 1/20 tablets ​

Nov 22 Glenmark Pharmaceuticals Ltd * Gets ANDA approval for HAILEY Fe 1/20 tablets ​ Source text - http://bit.ly/2hRulnp Further company coverage:

BRIEF-Glenmark Pharmaceuticals gets ANDA approval for Haileytm 24 FE 1 mg/20 mcg​

* Gets ANDA approval for Haileytm 24 fe 1 mg/20 mcg​ Source text for Eikon: Further company coverage:

BRIEF-India's Glenmark Pharmaceuticals Sept-qtr consol profit falls about 4 pct

* Sept quarter consol profit 2.14 billion rupees versus profit of 2.24 billion rupees last year

BRIEF-Glenmark Pharmaceuticals gets ANDA approval for aprepitant capsules USP​

* Says ‍Glenmark Pharmaceuticals receives ANDA approval for aprepitant capsules USP​ Source text - http://bit.ly/2gHsEFg Further company coverage:

BRIEF-Glenmark Pharmaceuticals gets ANDA approval from U.S. FDA for desonide lotion

* Gets ANDA approval from U.S. FDA for desonide lotion, 0.05 percent Source text - http://bit.ly/2frnZGG Further company coverage:

BRIEF-Jaguar subsidiary Napo and Glenmark pharma sign agreement returning key rights in 141 countries to Napo

* Jaguar subsidiary Napo Pharmaceuticals and Glenmark Pharmaceuticals sign agreement returning key rights in 141 countries to Napo, solidifying Jaguar’s global commercial control of Mytesi (Crofelemer), Jaguar’s fda-approved human drug

BRIEF-Glenmark Pharma gets ANDA approval for nitroglycerin sublingual tablets

* Says receives ANDA approval for nitroglycerin sublingual tablets usp, 0.3 mg, 0.4 mg, and 0.6 mg Source text for Eikon: Further company coverage:

Select another date: